Abstract:
Richard Jones: Although this probably wouldn’t be generally recognised as a nanotechnology business, and it is certainly not described as one by Merck, it has some features that make it rather a good model for successful nanotech firms in the future. Its major product is a class of molecules whose value depends on the rather subtle nanoscale arrangements these molecules take up, and the way in which those arrangements are altered by interactions with a nanostructured surface and with applied fields.